AML Relapse: How IDH-Inhibitor Drugs Work To Achieve Remission Before Stem-Cell Transplant
SHARE

Fact Checked

SurvivorNet Fact Checking and Medical Review Standards:  

The SurvivorNet News Team creates high quality medical information that complies with our industry leading standards for factual accuracy and sourcing from leading experts at academic medical institutions. Every news article is thoroughly fact-checked by our physician collaborators. We vet each piece of work for factual integrity, impartiality, and clearly label any professional conflicts.

All SurvivorNet articles adhere to the following standards:

  1. All studies and research papers cited are from reputable academic medical institutions or peer-reviewed journals.
  2. When we use data, statistics, or quotes these references link to the original source.
  3. All content related to new treatments, drugs, procedures, and so on must clearly describe availability, side effects, treatment target (such as triple negative breast cancer)
  4. All medical information on SurvivorNet is sourced from respected medical professionals with verified medical credentials and links are provided to these sources.
  5. We strive to give the reader relevant background information and include, clearly-sourced contextual health information in all articles. Readers are clearly alerted to any conflicts of interest from a medical source or the authors of a cited study.
/ Updated April 3rd, 2020

AML Relapse: How IDH-Inhibitor Drugs Work To Achieve Remission Before Stem-Cell Transplant

Medical Source: Dr. Tara Lin
University of Kansas Medical Center
×

“When we have a patient whose AML has come back, the goal is to get them into a remission so we can take them to a stem cell transplant.,” says Dr. Tara Lin, director, Acute Leukemia Program, University of Kansas Medical Center.  This starts with “Drugs such as Ivosidenib or Enasidenib, which  are important because they can help us get patients into remission and then bridge to transplant.”

Early trials and published trials of these drugs show that about 30% of these patients will go into remission. Among them, a smaller proportion of patients will go on to have a stem-cell transplant. That smaller proportion reflects that some patients, often older ones, who may choose not to go on to a stem cell transplant for reasons not fully disclosed.

Read More
“But that would be the be long-term goal certainly for a younger fit patient with an IDH-1 or IDH-2 mutation whose going to receive these drugs as therapy in relapse,” says Dr. Lin. “The goal would be to put them back into a remission not with the expectation that these oral drugs will keep them in remission forever but that we can put them into a deep enough remission so that we can take them on to transplant which, at least, has a potentially curative option.”

Learn more about SurvivorNet's rigorous medical review process.

Dr. Tara Lin is an Associate Professor of Medicine at The University of Kansas Medical Center. She specializes in acute leukemia and cancer stem cell targeted therapies. Read More

AML Relapse

Relapse is part of the journey for many patients with acute myeloid leukemia. The timing of the relapse plays a big role in which treatment route your doctor will advise.

NOW
PLAYING
Symptoms of Relapse in Acute Myeloid Leukemia (AML)
NOW
PLAYING
Acute Myeloid Leukemia (AML): Treatment Options After Relapse
NOW
PLAYING
What is The Treatment For Acute Myeloid Leukemia (AML) Patients After Relapse: Gilteritinib And FLT3 Inhibitors
NOW
PLAYING
What Are The Options For Patients When Acute Myeloid Leukemia Returns?

Related Articles

Overview

If Other Treatments Aren’t Working — Stem Cell Transplant May Be A Good Option In CLL

Overview

Amazing Remission for Father of Four Told He Had Just Hours To Live Twice After a Valentine’s Day Diagnosis

Oldest Patient ‘Cured’ of HIV Still in Remission 5 Years After Transplant for Leukemia

Dramatic Battle: Father Fighting Leukemia Fights to Get His Stem Cell Donor Into U.S. After Visa Denied

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.